

# Behavioural complaints in participants who underwent predictive testing for Huntington's disease

M-N W Witjes-Ané, A H Zwinderman, A Tibben, G-J B van Ommen, R A C Roos

*J Med Genet* 2002;**39**:857–862

Changes in mood and behaviour form the most variable symptoms of the clinical characteristics of Huntington's disease (HD).<sup>1</sup> Although the diagnosis is usually based on motor signs, behavioural changes occur as a first manifestation of HD in up to half of the patients.<sup>2,3</sup> Irritable behaviour, aggression, and depression are most commonly seen in the first phase of the disease.<sup>4</sup> Anxiety, obsessions, and apathy are also extremely common in HD. In certain families, major affective disorders may appear as early as 20 years before the onset of chorea and dementia.<sup>5</sup> However, with regard to the manifestation of psychiatric signs, there is a known difficulty in distinguishing between an intrinsic and a reactive pattern. The action of the disease is often intertwined with the reaction to the disease in diagnosed patients but also in "asymptomatic" (that is, absence of motor signs) subjects carrying the expansion of the CAG triplet repeat (henceforth referred to as "carriers" compared to "non-carriers"). As far as we are aware, only two studies have been reported regarding psychiatric symptoms in asymptomatic carriers compared to non-carriers.<sup>6,7</sup> A controlled psychiatric study reported by Shiwach and Norbury<sup>7</sup> showed that there was no significant increase in affective disorder in the former group. However, the whole predictive tested group showed a higher prevalence of psychiatric episodes than their partners. According to the authors it is, therefore, not plausible that depression is an early sign of HD in asymptomatic carriers. Depression and feelings of helplessness are indeed usually seen as a consequence of stressful events related to HD, like predictive testing in both carriers and non-carriers, even years after the predictive test result. Many studies have been reported on mood changes as a reactive pattern in both carriers and non-carriers,<sup>8,9</sup> but behavioural changes as a plausible first manifestation of HD have not been the subject of such extensive investigation. Only Berrios *et al*<sup>6</sup> reported higher measures of irritability in neurologically asymptomatic carriers, suggesting that this symptom can appear very early in the course of HD. The focus of most investigators in this group has been directed more towards cognitive and motor functioning.<sup>7,10–28</sup>

Differentiating between the behavioural changes inherent in HD and the well known impact of DNA testing is important in view of studying early markers of the disease onset. This is in line with Paulsen *et al*<sup>29</sup> who stated "Careful study of neuropsychiatric symptoms associated with HD is essential to help distinguish features that are pathognomonic from behaviours that are sensitive but not specific of the disease".

Therefore in the present explorative study, we investigated the following issues.

- Is there a difference between carriers and non-carriers in the outcome of the UHDRS behavioural assessment?
- Do age and gender play a role in developing behavioural complaints?
- Are a psychiatric history and the interval between DNA testing and first assessment associated with the development of behavioural complaints?
- Is there a change in behavioural complaints in carriers after 18 months? Do these differ from non-carriers?

## Key points

- Huntington's disease (HD) is characterised by involuntary movements, dementia, and psychiatric signs, the latter occurring as a first manifestation of the disease in up to half of the patients. However, diagnosis is usually based on the motor symptoms.
- In this explorative study, we compared the occurrence of behavioural complaints in 46 identified carriers for HD and in 88 non-carriers by single blind administration of the Unified Huntington's Disease Rating Scale (UHDRS). Follow up was performed after 18 months in 114 participants.
- No significant differences were found between carriers and non-carriers in demographics or neurological motor signs according to the UHDRS.
- Carriers complained more than non-carriers about sadness, low self-esteem, aggressive behaviour, and compulsions. This was mostly seen in women and persons aged 30 to 49 years. Carriers in this age group did not express significantly more anxiety than non-carriers. Younger non-carriers (20–29 years) were found to be more anxious than older ones.
- A history of depression and the interval between predictive testing and first assessment were associated with behavioural complaints in the non-carrier group only.
- At follow up after 18 months, carriers still complained about aggression, while complaints about mood and low self-esteem had disappeared.
- We speculate that aggressive behaviour in our carrier group may be seen as an initial sign intrinsic to HD, while the presence of complaints about mood and low self-esteem seems to be related to the impact of the predictive test. However, owing to the explorative nature of our study, we do not suggest that phenocconversion has occurred. Research focusing on the early detection of behavioural changes, using a broader instrument, is still indispensable.

Longitudinal investigation is needed because of the diagnostic inaccuracy in cross sectional assessment of patients, one reason being the variability in presentation early in the disease.<sup>30</sup> Also, knowledge about the progression of psychiatric, motor, and cognitive symptoms and their relationship is essential for research into neuroprotective treatments.

## METHODS

### Participants

Since the availability of direct mutation analysis between 1993<sup>31</sup> and 1998, 370 people with a 50% risk of developing

**Table 1** Group characteristics of 134 participants

DNA test	Carriers (n=46)	Non-carriers (n=88)	p
Gender, M/F	16/30	40/48	0.23*
Age at NPA, mean (range), years	39 (21–66)	42 (18–64)	0.16†
Education			
Less than secondary school	4 (9%)	6 (7%)	
Secondary school	29 (63%)	56 (64%)	0.78‡
Higher than secondary school/university	13 (28%)	26 (30%)	
Number of CAG repeats, median (range)	43 (39–51)	19 (14–34)	
Age in years at DNA result, mean (range)	39 (18–62)	36 (18–62)	0.09†
Time interval in months between DNA result and first NPA (n=127§), median (range)	43 (1–60)	36 (0–61)	<b>0.02‡</b>
History of depression, yes/no¶	14/30	18/70	0.15*
Use of neuroleptics			0.15*
Antidepressive drugs	2 (4%)	4 (5%)	
Anxiolytic drugs	3 (7%)	–	

\*Chi-square test; †t test; ‡Mann-Whitney test.

§Seven DNA results not yet known at time of neuropsychological assessment (NPA).

¶Two missing.

**Table 2** Mean of complaints assessed using the behavioural part of the UHDRS

DNA test	Carriers (n=45) Mean (SD), range	Non-carriers (n=88) Mean (SD), range	p*
UHDRS behavioural			
Sadness	2.58 (3.56), 0–16	1.33 (2.77), 0–16	<b>0.01</b>
Self-esteem	2.18 (4.04), 0–16	0.74 (2.09), 0–9	<b>0.007</b>
Anxiety	1.51 (2.94), 0–12	1.21 (2.62), 0–16	0.76
Suicidal thoughts	0.42 (1.64), 0–9	0.03 (0.24), 0–2	0.08
Aggression	1.51 (3.48), 0–16	0.38 (1.5), 0–9	<b>0.04</b>
Irritable behaviour	1.56 (3.37), 0–16	1.15 (2.65), 0–16	0.98
Obsessions	0.69 (2.35), 0–12	0.34 (1.65), 0–9	0.07
Compulsions	0.64 (2.29), 0–12	0.23 (1.75), 0–16	<b>0.03</b>

\*Mann-Whitney test.

Huntington's disease have travelled from all over The Netherlands to Leiden to undergo presymptomatic testing. Applicants were considered positive for HD when the number of (CAG) copies exceeded 35 repeats. Applicants with a repeat containing fewer than 27 copies were considered to be non-carriers. Those with a repeat number between 27 and 35 were considered intermediate.<sup>32</sup>

Applicants who were or who became symptomatic and, consequently, for whom DNA testing was confirmatory, were not invited to participate in this study (n=10). Between November 1997 and January 1999, 134 subjects (36% of the total group tested) underwent the initial assessment in this single blind study. The percentage of carriers who participated was lower (34%) compared to the whole group who applied for DNA testing (44%). There were no demographic differences between this group and non-participants. However, there was a minority of carriers between 40 and 60 years in the group of participants in comparison to non-carriers.<sup>33</sup>

Twelve participants had previously undergone the linkage test and received direct testing after 1993. For seven participants, the study design was double blind because they did not yet know the outcome of their DNA test on entry. Three participants had an intermediate result (CAG repeats 30, 30, 34) and were included in the present study in the non-carrier group, as they are unlikely to develop the disease.<sup>32</sup>

The study was approved by the Medical Ethics Committee from the LUMC and all participants gave their informed consent.

### Measures

All participants were requested not to disclose the result of the predictive test to the investigators. The protocol consisted of using open questions about complaints in daily functioning,

categorised by a psychological assistant and a psychologist (MNWA) into memory, concentration, motor, affect, behaviour, somatic, and others. Furthermore, the Unified Huntington's Disease Rating Scale (UHDRS) and an extended neuropsychological assessment<sup>33</sup> were evaluated. The protocol lasted for about four hours (break included). The second protocol was performed 18 months later with the exception of the medical history from the UHDRS, an intelligence test, and two memory tests. This shortened version of the protocol took about two hours.

### UHDRS

The UHDRS comprises questions about medical history, a motor examination, a cognitive assessment, a behavioural assessment, an assessment of functional ability, and completion of a medication form. There is a high degree of internal consistency within each of the domains and it is a valid instrument for assessing the clinical features of HD. Furthermore, it appears to be appropriate for repeated administration during clinical studies and for tracking changes.<sup>34</sup> The scores of the motor tests, assessed by a neurologist (JPPvV/RACR), were summed in a total motor score and a diagnosis was filled in (normal, minor soft signs, probable HD, or unquestionable HD). The motor assessment has an excellent degree of inter-rater reliability.<sup>34</sup> Complaints about affect and behavioural changes were investigated with the behavioural part of the UHDRS. Frequency and severity of complaints about mood/sadness, low self-esteem or guilt, anxiety, suicidal thoughts, disruptive or aggressive behaviour, irritable behaviour, obsessions, compulsions, delusions, and hallucinations were scored in five categories with respect to severity (0 = absent; 1 = slight, questionable; 2 = mild; 3 = moderate; 4 = severe) and frequency (0 = almost never; 1 = seldom; 2 =

sometimes; 3 = frequently; 4 = almost always). The behavioural part was reported orally by the participant only. The assessment was structurally performed by a trained psychological assistant and afterwards discussed under the supervision of a psychologist (MNWA).

### Statistical analysis

Data were analysed using the Statistical Package for Social Sciences (SPSS), version 10. To reduce the number of variables, the products of severity and frequency were calculated for each symptom. Variables that were not normally distributed were analysed with non-parametric tests. Differences between carriers and non-carriers during baseline and follow up were examined with Student's *t* test, chi-square test, Fisher's exact test, and Mann-Whitney U test, where appropriate. Spearman's rank correlation was calculated to analyse behavioural complaints in relation to motor functioning, with age and with the interval between DNA testing and first assessment. Age was kept for this purpose as a continuous variable. Afterwards, age was classified into three subgroups ( $\leq 29$  years, 30-49 years,  $\geq 50$  years) for further investigation of the group close to probable age of onset. The Wilcoxon signed ranks test was used to study changes within groups after 18 months. The Mann-Whitney U test was performed to investigate differences over time between carriers and non-carriers. Significance level was set at 0.01 while marginal findings are reported with a more liberal *p* level ( $< 0.05$ ).

## RESULTS

### Group characteristics

The group characteristics are described in table 1. The time interval between DNA testing and this study was marginally longer in carriers compared to non-carriers. Neither group showed significant differences in other variables.

Assessment of spontaneously reported complaints in daily functioning showed marginal differences in affect (15% carriers and 5% non-carriers) and behaviour (9% of the carriers reported irritability and/or aggression while 1% non-carriers mentioned anxiety) (Fisher's exact test,  $p=0.05$ ).

Carriers did not differ significantly from non-carriers with respect to the diagnosis based on the UHDRS motor assessment ( $n=124$ , Mann-Whitney U test,  $p=0.15$ ).<sup>33</sup>


### Comparison between carriers and non-carriers in behavioural complaints

Table 2 shows that carriers complained significantly more than non-carriers of sadness and low self-esteem and marginally in aggression and compulsions. Means are reported because the value of nearly all medians was zero. None of the participants complained about delusions or hallucinations. Spearman's rank correlation was performed to ensure that the differences found between the two groups were not because of the few carriers discovered to be motor affected. Marginal association with diagnosis based on the motor assessment and the total motor score was only found in non-carriers for low self-esteem ( $r=0.22$ ,  $p=0.05$ ;  $r=0.25$ ,  $p=0.02$ ).

### The role of age and gender in the occurrence of behavioural complaints

#### Age

In carriers no correlation was found between age and behavioural complaints. However, in the age category 30-49 years, carriers ( $n=30$ ) complained significantly more about low self-esteem and guilt ( $p=0.008$ ) and marginally about aggression ( $p=0.03$ ) compared to non-carriers ( $n=46$ ). Older carriers ( $\geq 50$  years,  $n=8$ ) reported significantly more complaints concerning sadness ( $p=0.007$ ) and obsessions ( $p=0.009$ ) than older non-carriers ( $n=27$ ). Younger carriers ( $\leq 29$  years,  $n=7$ )



**Figure 1** Frequency of behavioural complaints in participants with and without a history of depression. C with/without = carriers with/without a history of depression; NC with/without = non-carriers with/without a history of depression. Vertical arrows indicate significant differences. \* $p<0.05$ , \*\* $p<0.01$ , \*\*\* $p=0.000$ .

reported marginally more irritable behaviour ( $p=0.04$ ) compared to non-carriers of similar age ( $n=15$ ).

In non-carriers, age correlated marginally with anxiety ( $r=-0.23$ ,  $p=0.03$ ). The percentage of younger non-carriers reporting this complaint was higher than those over 50 years of age (50% *v* 11%).

#### Gender

Gender differences were not apparent in the total group, nor when we looked at carriers and non-carriers separately. No differences were found between male carriers and male non-carriers. Female carriers, however, complained marginally more about sadness ( $p=0.03$ ), low self-esteem ( $p=0.01$ ), and aggression ( $p=0.02$ ) than female non-carriers.

### Influence of psychiatric history on the development of behavioural complaints

Participants were asked about the presence of a psychiatric history for depression, obsessive-compulsive disorder, psychosis, suicidal ideation, and suicidal attempt (UHDRS items 34-36, yes/no answer). Thirty-two percent of the carriers reported a history of depression and 21% of the non-carriers (NS) (table 1). Five carriers (11%) and four non-carriers (5%) used medication (table 1). There was no significant relationship between intake of neuroleptics and history of depression ( $r=0.005$ ,  $p=0.96$ ).

Fig 1 illustrates the mean occurrence of behavioural complaints among participants with and without a history of depression. A history of depression was only associated with behavioural complaints among the non-carriers. Participants from this group with a history of depression differed significantly from participants without as far as sadness ( $p=0.008$ ), low self-esteem ( $p=0.000$ ), and anxiety ( $p=0.000$ ) were concerned, and marginally in obsessions ( $p=0.02$ ). Suicidal ideation in the past did not differ between the groups. A history of obsessive-compulsive disorder, psychosis, or attempted suicide was never reported.

### Influence of time interval between DNA testing and first assessment

In the non-carriers, significant positive correlations were seen with aggressive behaviour ( $r=0.29$ ,  $p=0.007$ ) and with irritable behaviour ( $r=0.36$ ,  $p=0.001$ ). No correlations were found in the carrier group between time since DNA testing and behavioural complaints.

**Table 3** Mean change of behavioural complaints in carriers and non-carriers 18 months after baseline

DNA test	Carriers (n=35) Mean* (SD), range	Non-carriers (n=78) Mean* (SD), range	p†
UHDRS behavioural			
Sadness	0.66 (3.09), -6-7	0.28 (3.15), -12-16	0.24
Self-esteem‡	1.09 (2.67), -1-12	0.32 (2.04), -4-9	<b>0.03</b>
Anxiety	0.02 (4.22), -12-12	0.22 (3.62), -12-16	0.46
Suicidal thoughts	0 (0.87), -4-3	0.01 (0.34), -2-2	0.73
Aggression	0.29 (2.48), -8-9	0.28 (1.77), -4-9	0.55
Irritable behaviour	0.11 (3.03), -6-9	0.15 (2.66), -6-9	0.57
Obsessions	-0.37 (2.09), -9-5	0.08 (2.29), -12-9	0.41
Compulsions	0.29 (3.2), -10-12	-0.14 (2.36), -9-16	0.53

\*Higher score = fewer complaints (baseline minus follow up).

†Mean changes over time between the two groups (Mann-Whitney test).

‡Significantly fewer complaints in carriers (Wilcoxon signed ranks test:  $p=0.007$ ).

### Comparison of behavioural complaints between baseline and follow up for both carriers and non-carriers

After 18 months, 114 (85%) participants had returned to our department for follow up. Reasons for drop out were the following: no response to second recruitment (four carriers and six non-carriers), private circumstances (one non-carrier), the protocol was too demanding (two carriers), it was of no use to do it (two carriers), no time (one non-carrier), no benefit (one non-carrier), not tracked down (one non-carrier), no reason (one carrier), and dead (one carrier). Three of the carriers who dropped out were rated during baseline as either having probable or unquestionable motor symptoms characteristic of HD.

There were no significant differences in demographics between carriers ( $n=36$ ) and non-carriers ( $n=78$ ). The shorter duration of the protocol meant that the neurologists had less of an opportunity to attend the investigation. Consequently, motor performance was assessed on 28 carriers and 53 non-carriers. Carriers differed marginally in the diagnosis ( $p=0.04$ ). This group showed slightly more "minor soft motor signs" than during the first protocol (24% instead of 21%) while non-carriers showed fewer "minor soft motor signs" (14% instead of 21%). Three carriers had a worse rating compared to baseline, that is, having now either probable or unquestionable HD, but this occurred also in two non-carriers. During follow up, carriers still differed significantly from non-carriers with respect to aggressive behaviour ( $p=0.004$ ) and now also marginally in obsessions ( $p=0.04$ ). This was not associated with motor disturbance because no associations were found between these behavioural complaints and the motor diagnosis ( $-0.35 \leq r \leq 0.10$ ,  $0.07 \leq p \leq 0.96$ ) nor the total motor score ( $-0.27 \leq r \leq -0.03$ ,  $0.16 \leq p \leq 0.90$ ). The total burden of behavioural complaints in carriers at baseline was not associated with worse motor scores at follow up (motor diagnosis  $r=-0.003$ ,  $p=0.99$ , total motor score  $r=-0.13$ ,  $p=0.50$ ). The significant difference for sadness and compulsion found between the two groups at baseline disappeared. Table 3 shows that after 18 months changes were minimal in both groups and overall slightly better. Within the carrier group, a significant decrease in low self-esteem was found. Moreover, a marginal difference was found between the two groups in the change over time for low self-esteem.

### DISCUSSION

We showed that carriers reported significantly more complaints about sadness and low self-esteem and marginally about aggression and compulsions. This was not associated with the degree to which they were motor affected. Within the age category 30-49 years, carriers expressed more low self-esteem and aggression compared to non-carriers. When 85% of the participants returned 18 months later for follow

up, changes were minimal in both groups but carriers differed significantly now in aggression compared to non-carriers. The decrease of sadness and low self-esteem we found in carriers was not the result of the predominance of complaints among the participants who dropped out of the study, because no differences in behavioural complaints were found between this group and the group who participated in our follow up (results not shown). Our results on aggression and depression are similar to a recently published study by Berrios *et al.*<sup>6</sup> These authors compared neurologically asymptomatic carriers with non-carriers in a double blind study. The groups did not differ in measures about depression but they did so in inwardly and outwardly directed irritability (that is, the possibility of self-harm and the possibility of angry action, respectively<sup>35</sup>), suggesting that this symptom can occur very early in the course of HD.

In contrast to Decruyenaere *et al.*<sup>36</sup> and Codori *et al.*<sup>37</sup> we could not confirm that carriers approaching age of onset are more anxious and manifest a higher post-test depression level. However, the presence of anxiety in younger non-carriers indicates that the impact of the DNA test could still be present in this group. Younger non-carriers could be more actively thinking about the consequence of the test result. Some non-carriers may have expected a different test result and they may have to rethink their plans for their future. Symptoms of depression and anxiety after predictive testing are indeed more likely in those who received a test result contradictory to the expected outcome (Vancouver group in Decruyenaere *et al.*<sup>36</sup>).<sup>38</sup> Other studies showed that the test result in some non-carriers did not alleviate problems or worries not related to HD, as expected by these test participants.<sup>39</sup> This could also explain the positive relationship we found between irritable and aggressive behaviour and the interval since DNA testing in the non-carrier group.

In our study group, female carriers differed marginally from female non-carriers in sadness, low self-esteem, and aggression. The lack of significant differences between male carriers and non-carriers might be because of less power in the subgroups because the number of males was smaller. The fact that no gender differences were found in our study is in line with Codori *et al.*<sup>37</sup> who suggested that women were just as well adjusted as men, but in contrast to Dudok de Wit *et al.*<sup>40</sup> who reported that being a woman was one of the factors associated with a higher level of post-test distress.

The occurrence of a history of depression was similar in the two groups. This may represent "regular" depression found in a large proportion of the population. Studies showed that people with a psychiatric history were more at risk of maladjustment following the test. (Vancouver group in Evers-Kiebooms and Decruyenaere<sup>41</sup>). However, the contribution of a history of depression in developing behavioural complaints was only evident in non-carriers (sadness, low self-esteem,

and anxiety). Surprisingly, in our study carriers with a history did not differ from carriers without one. These findings, again, might be because of lesser power in the subgroups. Another possible explanation would be in line with Berrios *et al*<sup>6</sup> who reported discrepancies in factor structure of the psychiatric morbidity found in carriers, comprising "personality" (extrapunitive, dominance, intrapunitive, outward and inward irritability) and non-carriers, comprising "anxiety". The authors suggest that the psychiatric morbidity affecting carriers may be the result of a subtle interaction between genetic factors and environment (for example, disturbed upbringing) whereas non-carriers would only be subjected to the latter, which would include anxiety.

The interval between predictive testing and the time of our study was not significantly associated with the presence of behavioural complaints in the carrier group. Other studies have reported that post-test intrusion level, hopelessness, and depressive symptoms disappear after one year.<sup>36,37</sup> Also, carriers and non-carriers were reported not to differ significantly in the long term (three years after disclosure of the DNA test) with regard to change from baseline on the investigated psychological variables (intrusive thoughts, avoidance of thoughts, and hopelessness).<sup>42</sup> These authors are in line with Wiggins *et al*<sup>43</sup> who concluded that predictive testing has maintained or even improved the psychological well being of carriers. The test result reduced uncertainty and provided an opportunity for appropriate planning.<sup>39</sup> Codori *et al*<sup>39,44</sup> suggest that those who ask for the test are self-selected and believe they can cope better with a bad result. However, participants who underwent the direct mutation test had more depressive symptoms at all follow ups than those tested for linkage, even in the non-carrier group.<sup>37</sup>

In summary, owing to the explorative nature of our study, we can only speculate that aggressive behaviour in our carrier group may be seen as an initial sign intrinsic to HD while mood and low self-esteem complaints are more likely to be a reaction to the predictive test. Of course, as shown in other published reports, depression is a clinical manifestation of HD,<sup>45</sup> but unfavourable genetic information does not generally produce syndromes of clinical depression.<sup>37</sup> The participants in our study did not present with these characteristics. The highest percentages in our group of carriers were seen in the categories slight and mild with the exception of low self-esteem and aggression, which showed approximately the same percentage in the categories slight, mild, moderate, and severe. Our findings about the occurrence of aggression in our carrier group are not as striking as reported by Berrios *et al*,<sup>6</sup> and we do not suggest that phenoconversion has already occurred. In this study, we wanted to assert the fact that research in early detection of psychiatric signs is indispensable so that patients and family can be informed how to cope with these stressful manifestations of HD. Until now, this issue has been in the background compared to research in motor and cognitive functioning. This was the reason that our study was limited to the behavioural assessment of the UHDRS. The recent development of the Problem Behaviours Assessment for Huntington Disease (PBA-HD)<sup>46</sup> may well resolve the lack, so far, of a broader instrument than the UHDRS. This semi-interview appears to be more suitable for investigating and describing the prevalence of behavioural symptoms. A review by Naarding *et al*<sup>47</sup> shows that most published studies on this subject are disappointing because of the lack of diagnostic criteria and adequate rating scales. The investigation of carriers and the comparison with patients at different stages of the disease, relating behavioural complaints to cognitive and motor signs, should further enhance our insight into the early disease processes.

#### ACKNOWLEDGEMENTS

Financial support was provided by the Netherlands Organisation for Scientific Research (NWO) grant 970-10-021 and in part by "Stichting

Duyn en Rhyn". Katwijk M Vegter-van der Vlis is thanked for her help in selecting potential participants and for providing information required with discretion. We are grateful to J P P van Vugt for assessing the motor part of the UHDRS and to F G Zitman and J B K Lanser for their helpful comments on the manuscript. The help of A Krijnen, M v d Heijden, P J Tazelaar, F Gronheid, L Fotiadis, and E de Wilde is gratefully acknowledged in assessing the protocols, as is the assistance of J de Vreugd, especially with data processing.

#### Authors' affiliations

**M-N W Witjes-Ané, A Tibben, R A C Roos**, Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands

**A H Zwinderman**, Department of Medical Statistics, Leiden University Medical Centre, Leiden, The Netherlands

**A Tibben**, Departments of Clinical Genetics and Neurology, Leiden University Medical Centre, Leiden, The Netherlands

**G-J B van Ommen**, Department of Human Genetics, Leiden University Medical Centre, Leiden, The Netherlands.

Correspondence to: Dr M-N W Witjes-Ané, Leiden University Medical Centre, Department of Neurology-Neuropsychology, J3-R, PO Box 9600, 2300 RC Leiden, The Netherlands; m.n.w.ane@lumc.nl

#### REFERENCES

- 1 **Caine ED**, Shoulson I. Psychiatric syndromes in Huntington's disease. *Am J Psychiatry* 1983;**140**:728-33.
- 2 **De Marchi N**, Mennella R. Huntington's disease and its association with psychopathology. *Harvard Rev Psychiatry* 2000;**7**:278-89.
- 3 **Mendez MF**. Huntington's disease: update and review of neuropsychiatric aspects. *Int J Psychiatry Med* 1994;**24**:189-208.
- 4 **Webb M**, Trzepacz PT. Huntington's disease: correlations of mental status with chorea. *Biol Psychiatry* 1987;**22**:751-61.
- 5 **Folstein SE**, Abbott MH, Chase GA, Jensen BA, Folstein MF. The association of affective disorder with Huntington's disease in a case series and in families. *Psychol Med* 1983;**13**:537-42.
- 6 **Berrios GE**, Wagle AC, Markova IS, Wagle SA, Rosser A, Hodges JR. Psychiatric symptoms in neurologically asymptomatic Huntington's disease gene carriers: a comparison with gene negative at risk subjects. *Acta Psychiatr Scand* 2002;**105**:224-30.
- 7 **Shiwach RS**, Norbury CG. A controlled psychiatric study of individuals at risk for Huntington's disease. *Br J Psychiatry* 1994;**165**:500-5.
- 8 **Broadstock M**, Michie S, Marteau T. Psychological consequences of predictive genetic testing: a systematic review. *Eur J Hum Genet* 2000;**8**:731-8.
- 9 **Meiser B**, Dunn S. Psychological impact of genetic testing for Huntington's disease: an update of the literature. *J Neural Neurosurg Psychiatry* 2000;**69**:574-78.
- 10 **Blackmore L**, Simpson SA, Crawford JR. Cognitive performance in UK sample of presymptomatic people carrying the gene for Huntington's disease. *J Med Genet* 1995;**32**:358-62.
- 11 **Campodonico JR**, Codori AM, Brandt J. Neuropsychological stability over two years in asymptomatic carriers of the Huntington's disease mutation. *J Neural Neurosurg Psychiatry* 1996;**61**:621-4.
- 12 **de Boo G**, Tibben A, Hermans J, Jennekens-Schinkel A, Lanser JBK, Maat-Kievit A, Roos RAC. Memory and learning are not impaired in presymptomatic gene carriers of Huntington's disease. *J Clin Exp Neuropsychol* 1999;**21**:831-6.
- 13 **de Boo GM**, Tibben A, Lanser JB, Jennekens-Schinkel A, Hermans J, Maat-Kievit A, Roos RA. Early cognitive and motor symptoms in identified carriers of the gene for Huntington disease. *Arch Neurol* 1997;**54**:1353-7.
- 14 **de Boo GM**, Tibben A, Lanser JB, Jennekens-Schinkel A, Hermans J, Vegter-van der Vlis M, Roos RA. Intelligence indices in people with a high/low risk for developing Huntington's disease. *J Med Genet* 1997;**34**:564-8.
- 15 **Diamond R**, White RF, Myers RH, Mastromauro C, Koroshetz WJ, Butters N, Rothstein DM, Moss MB, Vasterling J. Evidence of presymptomatic cognitive decline in Huntington's disease. *J Clin Exp Neuropsychol* 1992;**14**:961-75.
- 16 **Foroud T**, Siemers E, Kleindorfer D, Bill DJ, Hodes ME, Norton JA, Conneally PM, Christian JC. Cognitive scores in carriers of Huntington's disease gene compared to noncarriers. *Ann Neurol* 1995;**37**:657-64.
- 17 **Giordani B**, Berent S, Boivin MJ, Penney JB, Lehtinen S, Markel DS, Hollingsworth Z, Butterbaugh G, Hichwa RD, Gusella JF. Longitudinal neuropsychological and genetic linkage analysis of persons at risk for Huntington's disease. *Arch Neurol* 1995;**52**:59-64.
- 18 **Gómez-Tortosa E**, del Barrio A, Barroso T, García Ruiz PJ. Visual processing disorders in patients with Huntington's disease and asymptomatic carriers. *J Neural* 1996;**243**:286-92.
- 19 **Gray JM**, Young AW, Barker WA, Curtis A, Gibson D. Impaired recognition of disgust in Huntington's disease gene carriers. *Brain* 1997;**120**:2029-38.
- 20 **Hahn-Barma V**, Deweer B, Dürr A, Dodé C, Feingold J, Pillon B, Agid Y, Brice A, Dubois B. Are cognitive changes the first symptoms of Huntington's disease? A study of gene carriers. *J Neural Neurosurg Psychiatry* 1998;**64**:172-7.

- 21 **Jason GW**, Pajurkova EM, Suchowersky O, Hewitt J, Hilbert C, Reed J, Hayden MR. Presymptomatic neuropsychological impairment in Huntington's disease. *Arch Neurol* 1988;**45**:769-73.
- 22 **Kirkwood SC**, Siemers E, Stout JC, Hodes ME, Conneally PM, Christian JC, Foroud T. Longitudinal cognitive and motor changes among presymptomatic Huntington disease gene carriers. *Arch Neurol* 1999;**56**:563-8.
- 23 **Kirkwood SC**, Siemers E, Hodes ME, Conneally PM, Christian JC, Foroud T. Subtle changes among presymptomatic carriers of the Huntington's disease gene. *J Neurol Neurosurg Psychiatry* 2000;**69**:773-9.
- 24 **Lawrence AD**, Hodges JR, Rosser AE, Kershaw A, French-Constant C, Rubinsztein DC, Robbins TW, Sahakian BJ. Evidence for specific cognitive deficits in preclinical Huntington's disease. *Brain* 1998;**121**:1329-41.
- 25 **Lundervold AJ**, Reinvang I. Variability in cognitive function among persons at high genetic risk of Huntington's disease. *Acta Neurol Scand* 1995;**91**:462-9.
- 26 **Rosenberg NK**, Sorensen SA, Christensen A. Neuropsychological characteristics of Huntington's disease carriers: a double-blind study. *J Med Genet* 2001;**32**:600-4.
- 27 **Rothlind JC**, Brandt J, Zee D, Codori AM, Folstein S. Unimpaired verbal memory and oculomotor control in asymptomatic adults with the genetic marker for Huntington's disease (published erratum appears in *Arch Neurol* 1994;**51**:268). *Arch Neurol* 1993;**50**:799-802.
- 28 **Strauss ME**, Brandt J. Are there neuropsychologic manifestations of the gene for Huntington's disease in asymptomatic, at-risk individuals? *Arch Neurol* 1990;**47**:905-8.
- 29 **Paulsen JS**, Ready RE, Hamilton JM, Mega MS, Cummings JL. Neuropsychiatric aspects of Huntington's disease. *J Neurol Neurosurg Psychiatry* 2001;**71**:310-14.
- 30 **Whitehouse PJ**, Friedland RP, Strauss ME. Neuropsychiatric aspects of degenerative dementias associated with motor dysfunction. In: Yudofsky SC, ed. *The American psychiatric press textbook of neuropsychiatry*. Washington DC: American Psychiatric Press, 1992:585-604.
- 31 **The Huntington's Disease Collaborative Research Group**. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. *Cell* 1993;**72**:971-83.
- 32 **ACMG/ASHG statement**. Laboratory guidelines for Huntington disease genetic testing. The American College of Medical Genetics/American Society of Human Genetics Huntington Disease Genetic Testing Working Group. *Am J Hum Genet* 1998;**62**:1243-7.
- 33 **Witjes-Ané MNW**, Vegter-van der Vlis M, van Vugt JPP, Lanser JKB, Hermans J, Zwinderman AH, van Ommen GJB, Roos RAC. Cognitive and motor functioning in gene-carriers for Huntington's disease: a baseline study. *J Neuropsychiatry Clin Neurosci* (in press).
- 34 **Huntington Study Group**. Unified Huntington's Disease Rating Scale: reliability and consistency. *Mov Disord* 1996;**11**:136-42.
- 35 **Snaitth RP**, Constantopoulos AA, Jardine MY, McGuffin P. A clinical scale for the self-assessment of irritability. *Br J Psychiatry* 1978;**132**:164-71.
- 36 **Decruyenaere M**, Evers-Kiebooms G, Boogaerts A, Cassiman JJ, Cloostermans T, Demyttenaere K, Dom R, Fryns JP. Psychological functioning before predictive testing for Huntington's disease: the role of parental disease, risk perception, and subjective proximity of the disease. *J Med Genet* 1999;**36**:897-905.
- 37 **Codori AM**, Slavney PR, Young C, Miglioretti DL, Brandt J. Predictors of psychological adjustment to genetic testing for Huntington's disease. *Health Psychol* 1997;**16**:36-50.
- 38 **Tibben A**, Duivenvoorden HJ, Vegter-van der Vlis M, Niermeijer MF, Frets PG, van der Kamp JJP, Roos RAC, Rooijmans HGM, Verhage F. Presymptomatic DNA testing for Huntington disease: identifying the need for psychological intervention. *Am J Med Genet* 1993;**48**:137-44.
- 39 **Codori AM**, Brandt J. Psychological costs and benefits of predictive testing for Huntington's disease. *Am J Med Genet* 1994;**54**:174-84.
- 40 **Dudok de Wit AC**. To know or not to know. The psychological implications of presymptomatic DNA testing for autosomal dominant inheritable late onset disorders. Thesis, Erasmus University, Rotterdam, The Netherlands, 1997.
- 41 **Evers-Kiebooms G**, Decruyenaere M. Predictive testing for Huntington's disease: a challenge for persons at risk and professionals. *Patient Educ Couns* 1998;**35**:15-26.
- 42 **Tibben A**, Timman R, Bannink EC, Duivenvoorden HJ. Three-year follow-up after presymptomatic testing for Huntington's disease in tested individuals and partners. *Health Psychol* 1997;**16**:20-35.
- 43 **Wiggins S**, Whyte P, Huggins M, Adam S, Theilmann J, Bloch M, Sheps SB, Schechter MT, Hayden MR. The psychological consequences of predictive testing for Huntington's disease. *N Engl J Med* 1992;**327**:1401-5.
- 44 **Codori AM**, Hanson R, Brandt J. Self-selection in predictive testing for Huntington's disease. *Am J Med Genet* 1994;**54**:167-73.
- 45 **Slaughter JR**, Martens PM, Slaughter KA. Depression and Huntington's disease: prevalence, clinical manifestations, etiology and treatment. *CNS Spectrums* 2001;**6**:306-26.
- 46 **Craufurd D**, Thompson JC, Snowden JS. Behavioral changes in Huntington disease. *Neuropsychiatr Neuropsychol Behav Neurol* 2001;**14**:219-26.
- 47 **Naarding P**, Kremer HPH, Zitman FG. Huntington's disease: a review of the literature on prevalence and treatment of neuropsychiatric phenomena. *Eur J Psychiatry* 2001;**16**:439-45.